Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.35
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€219.01M
Enterprise Value€305.98M
Total Cash (Recent Filing)€21.58M
Total Debt (Recent Filing)€103.27M
Price to Earnings (P/E)49.3
Beta0.36
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.73%
Share Statistics
EPS (TTM)0.05
Shares Outstanding82,883,400
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelRJF’s mixed revenue streams — branded/specialty pharmaceuticals plus CDMO manufacturing — create durable cash and contractual revenue sources. CDMO contracts can provide backlog and capacity utilization that smooth cyclicality in product sales and support recovery after demand shocks.
Historical Cash Generation (2022–24)Prior multi-year positive free cash flow shows the business can convert earnings into cash under normal conditions, supporting reinvestment, dividends, and debt service. That historical conversion capacity suggests the company can restore cash generation if revenue and margins stabilize.
Moderate Leverage And Equity GrowthHistorically moderate debt-to-equity (roughly 0.26–0.36) and steady equity expansion indicate a resilient balance sheet foundation. This gives the company structural room to absorb shocks, access funding, and finance working capital or capex without being structurally overlevered.
Bears Say
Sharp 2025 Revenue And Margin DeclineA large revenue drop and collapse in operating and net margins materially weaken the company’s earnings power. Such deterioration can signal structural demand loss, pricing pressure, or cost issues that erode operating leverage and make it harder to generate sustainable profits over the medium term.
Free Cash Flow Turned Sharply Negative In 2025Negative free cash flow in 2025 reduces liquidity and increases reliance on external financing or asset sales. Persistent or repeated FCF deficits constrict reinvestment, R&D and capacity upkeep, which can damage long-term competitiveness and hinder recovery even if revenues rebound.
Rising Leverage In 2025An uptick in leverage amid falling profits raises fixed-charge risk and reduces financial flexibility. Higher debt burdens make it harder to absorb future shocks or invest in growth, and amplify downside if margins remain compressed, increasing refinancing and covenant vulnerability.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.35 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €219.01M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is in 8 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on May 07, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 0.73%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,883,400 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.087%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.